|
Match
|
Document |
Document Title |
|
|
US20120009125 |
APOE4 AND APOJ BIOMARKER-BASED PREVENTION AND TREATMENT OF DEMENTIA
Methods, kits, screens, assays, treatments and treatment regimes for treating a patient at risk for or suffering from dementia, and particularly Alzheimer's dementia which are based upon...
|
|
|
US20110182928 |
VACCINE AGAINST AMYLOID FOLDING INTERMEDIATE
The invention relates to an improved vaccine to treat Alzheimer's disease.
|
|
|
US20120021971 |
Functional Food Product Comprising Heat Shock Protein or a Hydrolysate Thereof
The invention relates to a heat shock protein from alfalfa and/or a hydrolysate of a heat shock protein from alfalfa in the manufacture of a food product for the prophylactic or therapeutic...
|
|
|
US20120100116 |
NEURON GENERATION, REGENERATION AND PROTECTION
The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth...
|
|
|
US20110256130 |
METHODS OF TREATING INFLAMMATORY DISORDERS
Disclosed herein, in certain embodiments, are methods and compositions for treating inflammatory disorders. In some embodiments, the methods comprise co-administering synergistic combinations of...
|
|
|
US20120058099 |
USE OF HYPOXANTHINE FOR PROMOTION OF NEURONAL OUTGROWTH
Disclosed herein is a method of promoting neuronal outgrowth in a neuron. The method comprises contacting the neuron with an effective amount of hypoxanthine, to thereby promote neuronal outgrowth...
|
|
|
US20110070237 |
METHODS OF MODULATING AND IDENTIFYING AGENTS THAT MODULATE INTRACELLULAR CALCIUM
Methods are provided for identifying agents that modulate intracellular calcium. Also provided are methods of modulating calcium within cells and methods of identifying proteins involved in...
|
|
|
US20110190730 |
METHODS OF INDUCING PLURIPOTENCY INVOLVING OCT4 PROTEIN
The invention relates to a method of inducing pluripotency in a responsive mammalian cell, which comprises introducing into the cell an effective amount for initiating pluripotency within the cell...
|
|
|
US20110182948 |
METHOD FOR TREATING DISEASE CHARACTERIZED BY PLAQUE
The present invention relates to the use of a filamentous agent other than a filamentous bacteriophage to disaggregate aggregated proteins in plaque or to treat a patient suffering from or...
|
|
|
US20120010132 |
METHODS FOR TREATING PROGRESSIVE COGNITIVE DISORDERS RELATED TO NEUROFIBRILLARY TANGLES
The described invention provides methods for treating or preventing progression of a progressive cognitive disease, disorder or condition, and methods for improving resilience of cognitive function...
|
|
|
US20110212895 |
Treatment of Cognitive and Learning Impairment
Constitutive activators of Rho GTPases are useful in treating learning an cognitive disorders.
|
|
|
US20110166075 |
METHOD OF TREATING DEGENERATIVE DISORDERS OF THE NERVOUS SYSTEM BY ADMINISTRATION OF FIBRINOGEN FRAGMENT
The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise peptides that bind to receptors important in disease progression, thus...
|
|
|
US20100303824 |
SIGNALING INTERMEDIATES IN AN IN VITRO MODEL OF ALZHEIMER'S DISEASE
The invention provides a novel human protein, FISH adaptor protein, involved in amyloid β-protein-mediated cell death. Also provided are methods for modulating amyloid β-protein-mediated cell d...
|
|
|
US20110269689 |
HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS
High penetration compositions (HPC) of a parent compound, which are capable of crossing biological barriers with high penetration efficiency. The HPCs are capable of being converted to parent drugs...
|
|
|
US20110190729 |
METHODS OF INDUCING PLURIPOTENCY INVOLVING SOX2 PROTEIN
The invention relates to a method of inducing pluripotency in a responsive mammalian cell, which comprises introducing into the cell an effective amount for initiating pluripotency within the cell...
|
|
|
US20110021413 |
METHODS OF SUPPRESSING MICROGLIAL ACTIVATION
Methods of suppressing the activation of microglial cells in the Central Nervous System (CNS), methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral...
|
|
|
US20110201558 |
Anaplerotic Therapy for Alzheimer's Disease and the Aging Brain
The present invention describes methods and compositions for the treatment of neurodegenerative conditions including Alzheimer's disease (AD) and aging. The present invention discloses an...
|
|
|
US20110142795 |
METHODS OF TREATING COGNITIVE IMPAIRMENT
The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or...
|
|
|
US20110318358 |
IMMUNOTHERAPY FOR CLEARING PATHOLOGICAL TAU CONFORMERS
The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies...
|
|
|
US20110104181 |
MODULATION OF SYNAPTOGENESIS
The present invention describes methods and compositions for modulating synaptogenesis and axon and/or dendritic growth. The methods include the use of agents that modulate a thrombospondin and/or...
|
|
|
US20110189165 |
METHOD OF IDENTIFYING DISEASE RISK FACTORS
Provided herein is a method for identifying a genetic variant that is associated with development of a condition of interest (e.g., Alzheimer's disease), and genetic variants so identified. Methods...
|
|
|
US20110200564 |
DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE (AD)
Disclosed herein are novel methods, assays and systems for detecting an increased risk for Alzheimer's disease (AD) in a subject by identifying at least one nuclei acid polymorphism described...
|
|
|
US20110112035 |
THERAPEUTIC USE OF A GROWTH FACTOR, METRNL
The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL,...
|
|
|
US20120021992 |
METHODS FOR IMPROVING NEUROLOGICAL OUTCOME AFTER NEURAL INJURY AND NEURODEGENERATIVE DISEASE
Thymosin β4 can be used to treat neuronal and brain injuries that are accompanied by neuronal cell death or injury, including injuries caused by stroke or trauma and injuries caused by ...
|
|
|
US20110293635 |
COMPOSITION AND METHODS FOR MODULATING TOLL-LIKE RECEPTOR ACTIVITY
The present invention relates to compositions and methods for use in the treatment of conditions such as septicaemia and septic shock. The invention further provides compositions and methods for...
|
|
|
US20120058938 |
NUTRITIONAL COMPOSITION INDUCING A POSTPRANDIAL ENDOCRINE RESPONSE
The invention concerns the use of a nutritional composition for the treatment of disorders which are associated with malfunctioning in the uptake and use of food-derived energy in the human body....
|
|
|
US20110135607 |
VIRAL NUCLEIC ACID FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
This invention relates to a non-coding RNA (ncRNA) sequence from Human cytomegalovirus (HCMV) (termed “TRL4”) that specifically protects neuronal cells from cell death and may therefore be use...
|
|
|
US20120122765 |
COMPOUNDS AND RELATED METHODS FOR MANIPULATING PARP-1-DEPENDENT CELL DEATH
Apoptosis inducing factor (“AIF”) contains a PAR-binding motif (“PBM”) that binds to Poly(ADP-ribose) (“PAR”). Binding of PAR to AIF via the PBM is required for AIF release from the mitochondri...
|
|
|
US20110262442 |
COMPOSITIONS FOR TREATING CNS DISORDERS
The present invention provides combination therapies for treating a disease, disorder, or condition, and methods thereof.
|
|
|
US20110065645 |
Compositions and Methods for Modulating Neuron Degeneration and Neuron Guidance
Methods for inhibiting degeneration of a neuron, methods of treating a neurodegenerative disease, methods for promoting degeneration of a neuron are provided, methods for modulating neuron cell...
|
|
|
US20120129780 |
LACTOFERRIN AND BRAIN HEALTH AND PROTECTION IN ADULTS
The present invention relates generally to the field of brain health, brain protection, maintenance of cognitive function, prevention of cognitive decline and cognitive disorders. Neuronal cells in...
|
|
|
US20110081323 |
Methods and compositions for organ and tissue functionality
Materials and methods for treating tissue defects in human or animal tissues using implantable cells are described. Further, culture techniques and factors for enhancing these procedures, and cell...
|
|
|
US20120122794 |
Compound And Method For Treatment Of Alzheimer's Disease
An isolated protein selected from the group consisting of (i) proteins comprising an amino acid sequence having at least 70% identity to the C-terminal domain of lung surfactant protein C precursor...
|
|
|
US20060062859 |
Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes
The present invention relates to a composition and custom business model and methods to measure genetic and metabolomic contributing factors affecting disease diagnosis, stratification, and...
|
|
|
US20110319317 |
TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRT1
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sirtuin 1 (SIRT1), in particular, by targeting natural antisense polynucleotides of...
|
|
|
US20110015131 |
METHODS FOR PREVENTING AND TREATING ALZHEIMER'S DISEASE (AD)
The present invention relates to methods for preventing Alzheimer's disease (AD) with an Aβ42 mimotope and binds to an antibody specific for DAEFRH (SEQ ID NO: 1) which is a part of the ...
|
|
|
US20110318346 |
Alpha B-crystallin as a therapy for Ischemia or inflammation
The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is...
|
|
|
US20110172143 |
METHOD OF MODULATING CELL SURVIVAL AND REAGENTS USEFUL FOR SAME
The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival...
|
|
|
US20110143992 |
Methods and Compositions Related to GHS-R Antagonists
Disclosed herein are methods and compositions related to GHS-R antagonists.
|
|
|
US20110294741 |
USE OF COMPOUNDS IN THE TREATMENT OF TAU-INDUCED CYTOTOXICITIES
The present invention relates to derivatives of L-Tyrosyl-L-Arginine and the use of said derivatives in the prevention and/or treatment of a tau-induced cytotoxicity.
|
|
|
US20110112034 |
Modulation of synaptogenesis
Soluble proteins, e.g. thrombospondins, can trigger synapse formation. Such proteins are synthesized in vitro and in vivo by astrocytes, which therefore have a role in synaptogenesis. These...
|
|
|
US20110218152 |
COMPOUNDS FOR STIMULATING P-GLYCOPROTEIN FUNCTION AND USES THEREOF
The present invention is directed to polypeptides (e.g., fragments) derived from P-glycoprotein and caveolin-1 which are capable of inhibiting the interaction between these two proteins. Inhibition...
|
|
|
US20120076785 |
METHOD FOR INHIBITING NEURODEGENERATION
Methods for screening for compounds that inhibit neurodegeneration are presented. Shedding of APP can be a useful marker for neurodegeneration and compounds that inhibit shedding of APP are useful...
|
|
|
US20070087406 |
Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same
Isoforms of RAGE and pharmaceutical compositions containing RAGE isoforms are provided. Methods for identifying and preparing RAGE isoforms are provided. Also provided are methods of treatment with...
|
|
|
US20120115791 |
Methods for Treating Immune Mediated Neurological Diseases
Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune...
|
|
|
US20080020975 |
Galanin Receptors and Brain Injury
There is provided the use of a GALR2-specific agonist in the preparation of a medicament for the prevention or treatment of brain injury, damage or disease, wherein the brain injury or damage is...
|
|
|
US20110144029 |
Model Systems and Materials for the Study and Treatment of Neurodegenerative Diseases
The present invention provides models for studying the development of, and/or pathologies associated with neurodegenerative diseases, and agents that can modulate such development and/or pathologies.
|
|
|
US20100278743 |
METHODS FOR TREATMENT AND PREVENTION OF TAUOPATHIES AND AMYLOID BETA AMYLOIDOSIS BY MODULATING CRF RECEPTOR SIGNALING
Methods for treating or preventing tauopathies and/or Aβ amyloidosis by modulating CRF receptor signaling. Accumulation of hyperphosphorlyated tau protein in the CNS may be reduced by ...
|
|
|
US20120046217 |
TNF-alpha Antagonists Containing IGFBP5
The present invention relates to: TNF-α antagonists containing IGFBP5 protein, variants thereof, or fragments thereof; and the use of the TNF-α antagonists. More specifically, the present i...
|
|
|
US20110123512 |
METHOD OF REGULATING THE HEAT SHOCK RESPONSE
The present invention is directed to method of modulating a heat shock response in a first cell of a multicellular organism comprising stimulating or inhibiting an HSR signaling activity of a...
|